Dr. Gadgeel Reflects on Progress in Lung Cancer at IASLC 2024 World Conference on Lung Cancer

Shirish M. Gadgeel, MD, of the Henry Ford Cancer Institute and the Henry Ford Health System, reflects on the progress in lung cancer treatment during the IASLC 2024 World Conference on Lung Cancer.

“This conference, in my opinion, now has become another stop on this journey that started about 10-15 years ago where we have these new targeted treatments and immunotherapy,” Dr. Gadgeel said. “That has completely changed the landscape of lung cancer management, and I think we are only at the beginning.”

Dr. Gadgeel spoke about how the field, treatment options, and patient outcomes have evolved since he began practicing.

“When I started 23 years ago, the average survival of advanced stage lung cancer patients was 7 to 8 months,” he said. “Today in my practice, I have stage IV lung cancer patients who are alive 13 to 14 years after they were diagnosed… I just look forward to what further advances we’re going to see at conferences like this that are going to improve the outcomes of our patients.”